Want to see GB:CNSL full AI Analyst Report?
CNSL Stock Chart & Stats
1.85 p
-0.06 p(-3.71%)
At close: 4:00 PM EDT
1.85 p
-0.06 p(-3.71%)
Day’s Range― - ―
52-Week Range1.26 p - 2.80 p
Previous CloseN/A
Volume526.81K
Average Volume (3M)608.57K
Market Cap
£3.69M
Enterprise Value1.89M
Total Cash (Recent Filing)£2.64M
Total Debt (Recent Filing)£125.00K
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Nov 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding237,950,650
10 Day Avg. Volume562,274
30 Day Avg. Volume608,570
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.77
Price to Sales (P/S)0.63
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageThe company’s very low leverage limits balance-sheet risk and preserves financial flexibility compared with a highly indebted business. This provides greater scope to manage operating volatility, fund necessary investment, or withstand weaker trading without the additional burden of substantial interest and refinancing obligations.
Resilient Gross MarginsA consistently solid gross margin indicates that Omega retains meaningful value capture across its diagnostic products and components, even when revenue and earnings fluctuate. Maintaining this margin structure could support recovery if sales stabilize, although operating execution must improve for it to translate into profits.
Established IVD PlatformOmega operates across development, manufacturing, and supply of in-vitro diagnostic products rather than relying on a single testing format. Its presence in both rapid and laboratory-format immunoassays provides an established platform from which healthcare and laboratory demand can be served over time.
Bears Say
Revenue ContractionRecent revenue contraction signals weakening commercial momentum after the 2024 rebound. Two consecutive years without sustained growth can reduce operating leverage, limit investment capacity, and make it harder for the company to absorb fixed costs, leaving the near-term earnings outlook dependent on a return to demand growth.
Severe Profitability DeteriorationThe sharp reversal from profitability to a very heavy net loss demonstrates that earnings are not yet dependable. Even with gross margin near 61%, the scale of the deterioration suggests substantial pressure below gross profit, weakening internal funding capacity and reducing confidence in sustainable earnings over the next several quarters.
Renewed Cash BurnRenewed operating and free cash outflows after the positive 2024 inflection indicate that cash generation remains inconsistent. Persistent burn can constrain reinvestment, increase reliance on external funding, and weaken the company’s ability to convert its diagnostic activities and gross margin into durable financial resources.
Omega Diagnostics News
CNSL FAQ
What was Omega Diagnostics Group PLC’s price range in the past 12 months?
Omega Diagnostics Group PLC lowest share price was 1.25 p and its highest was 2.80 p in the past 12 months.
What is Omega Diagnostics Group PLC’s market cap?
Omega Diagnostics Group PLC’s market cap is £3.69M.
When is Omega Diagnostics Group PLC’s upcoming earnings report date?
Omega Diagnostics Group PLC’s upcoming earnings report date is Nov 19, 2026 which is in 26 days.
How were Omega Diagnostics Group PLC’s earnings last quarter?
Omega Diagnostics Group PLC released its earnings results on Sep 08, 2026. The company reported -0.01 p earnings per share for the quarter, missing the consensus estimate of -0.001 p by -0.009 p.
Is Omega Diagnostics Group PLC overvalued?
According to Wall Street analysts Omega Diagnostics Group PLC’s price is currently Overvalued.
Does Omega Diagnostics Group PLC pay dividends?
Omega Diagnostics Group PLC does not currently pay dividends.
What is Omega Diagnostics Group PLC’s EPS estimate?
Omega Diagnostics Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Omega Diagnostics Group PLC have?
Omega Diagnostics Group PLC has 237,950,650 shares outstanding.
What happened to Omega Diagnostics Group PLC’s price movement after its last earnings report?
Omega Diagnostics Group PLC reported an EPS of -0.01 p in its last earnings report, missing expectations of -0.001 p. Following the earnings report the stock price went down -24.324%.
Which hedge fund is a major shareholder of Omega Diagnostics Group PLC?
Currently, no hedge funds are holding shares in GB:CNSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Omega Diagnostics Group PLC
Established in 1987 and headquartered in London, UK, Cambridge Nutritional Sciences plc (formerly Omega Diagnostics Group PLC until its name change in September 2023) is a specialist in the development, manufacturing, and supply of medical diagnostic products. The company primarily operates within the food sensitivity testing market, creating and producing "Foodprint" branded kits designed to detect immune reactions to food. Beyond manufacturing, it provides clinical analysis services directly to the public, clinics, and healthcare professionals, and also offers the "Food Detective" consumer food test. Its diverse client base includes government entities, private hospitals, reference laboratories, nutritionists, naturopaths, and other medical practitioners. Cambridge Nutritional Sciences plc boasts a global presence, serving markets across the United Kingdom, continental Europe, North, South, and Central America, India, various other Asian countries and the Far East, Africa, and the Middle East.
Technical Analysis
Advanced Medical Solutions
―
EKF Diagnostics Holdings
―
IXICO plc
―
Tristel
―
Abingdon Health PLC
―